Prasad, P., & Prasad, M. (2024). In Reply: Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease? Cleveland Clinic Journal of Medicine, 91(2), 82.2-83. https://doi.org/10.3949/ccjm.91c.02002

Calì, F., & Pinsino, A. (2024). Heart Failure Guideline-Directed Medical Therapy in End-Stage Kidney Disease: From PARADIGM-HF to Clinical Practice. Kidney International Reports, 9(1), 13–15. https://doi.org/10.1016/j.ekir.2023.11.015

Sekerak, R., Lerner, J. B.-A., Prasad, P., & Prasad, M. (2023). Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease? Cleveland Clinic Journal of Medicine, 90(10), 607–609. https://doi.org/10.3949/ccjm.90a.23004

Cohen, L. P., Isaza, N., Hernandez, I., Lewis, G. D., Ho, J. E., Fonarow, G. C., Kazi, D. S., & Bellows, B. K. (2023). Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 8(5), 419. https://doi.org/10.1001/jamacardio.2023.0077